"The ACOMS Annual Meeting provides an excellent forum for AxoGen to connect with surgeons actively treating or referring patients for treatment of their nerve injuries and to present our full portfolio of nerve repair products.” - Jill Schiaparelli, SVP
Alachua, FL (PRWEB) April 28, 2014
AxoGen, Inc. (NASDAQ: AXGN), the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, announced today that it will be highlighting its products at the American College of Oral and Maxillofacial (ACOMS) 35th Annual Scientific Conference and Exhibition, April 27-30 in Las Vegas, Nevada. AxoGen is exhibiting its full portfolio of nerve repair and protection technologies and products at Booth 22.
The 2014 ACOMS meeting is entitled Orthognathic and Esthetic Surgery: A New Horizon and will focus on providing education on innovation and advances in surgical excellence in oral maxillofacial surgery
“Patients with oral nerve injuries, usually caused by common dental procedures such as wisdom tooth removal, are actively seeking options for surgical repair,” said AxoGen Senior Vice President of Marketing and Business Strategy, Jill Schiaparelli. “The ACOMS Annual Meeting provides an excellent forum for AxoGen to connect with surgeons actively treating or referring patients for treatment of their nerve injuries and to present our full portfolio of nerve repair products.”
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2014 revenue estimate, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: AxoGen, Inc.